[1]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120-123.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(05):120-123.[doi:10.3969/j.issn.1671-7414.2021.05.027]
点击复制

帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年05期
页码:
120-123
栏目:
检验与临床
出版日期:
2021-10-14

文章信息/Info

Title:
Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period
文章编号:
1671-7414（2021）05-120-05
作者:
李群英; 甄时建; 何树光; 陈超英
（湖南中医药高等专科学校附属第一医院检验科，湖南株洲 412000）
Author(s):
LI Qun-ying;  ZHEN Shi-jian;  HE Shu-guang;  CHEN Chao-ying
（Department of Clinical Laboratory, the First Affiliated Hospital of Hunan Traditional Chinese Medical College, HunanZhuzhou 412000, China）
关键词:
帕金森病; 血清微小RNA-153; 微小RNA-128b; 非运动症状
分类号:
R742；R392.11
DOI:
10.3969/j.issn.1671-7414.2021.05.027
文献标志码:
A
摘要:
目的　观察并对比帕金森病患者不同治疗时期非运动症状[非运动症状评价量表（NMSS）]与血清微小RNA-153（miR-153）和微小RNA-128b（miR-128b）表达谱，并分析NMSS评分与miR-153和miR-128b之间的相关性，旨在为临床诸多帕金森病患者的非运动症状治疗提供新的干预靶点。方法　前瞻性研究，选取湖南中医药高等专科学校附属第一医院2018年1月~2019年10月期间收治的82例帕金森患者，对所有患者均进行有效追踪，患者分别于治疗前、治疗4，8和12周于该院门诊复查，采用NMSS量表评估患者非运动症状，并检测血清miR-153和miR-128b水平，采用双变量Pearson相关性检验与一般线性回归分析得到线性回归方程，检验血清miR-153和miR-128b对帕金森患者非运动症状的影响。结果　治疗前血清miR-153和miR-128b表达谱及NMSS评分＞治疗4w＞治疗8w＞治疗12w，差异均有统计学意义（F=7.640，134.902，18.048，均P＜0.05）；经相关性分析得出：NMSS评分与血清miR-153和miR-128b表达谱均呈正相关（r=0.246，0.486，均P＜0.001）；经线性回归分析检验得到血清miR-153线性回归方程：Y=13.656+1.704X，血清miR-128b：Y=13.656+22.661X，帕金森患者血清miR-128b水平可能是患者非运动症状的影响因素（t=8.879，P＜0.05）。结论　帕金森病患者血清miR-153和miR-128b表达谱与非运动症状密切相关，临床可通过监测并干预血清miR-153和miR-128b表达谱，以此缓解帕金森病患者非运动症状，提高患者预后。
Abstract:
Objective　To observe and compare the expression profiles of non-motor symptoms [non-motor symptoms scale(NMSS)], serum microRNA-153 (miR-153) and microRNA-128b (miR-128b) in patients with Parkinson’s disease at differenttreatment periods, and analyze the correlation between the NMSS score and miR-153 and miR-128b, aiming to provide newintervention targets for the treatment of non-motor symptoms in many patients with Parkinson’s disease. Methods　Aprospective study was performed, 82 patients with Parkinson’s disease admitted to the First Affiliated Hospital of HunanTraditional Chinese Medicine College from January 2018 to October 2019 were selected, and all patients were effectivelytracked. The patients were reexamined in the outpatient department of the hospital before, at 4w, 8w and 12w of treatment, theNMSS scale was used to assess the symptoms of patients with non-motor symptoms, and detected serum miR-153, miR-128blevels, a bivariate Pearson correlation test and general linear regression analysis were used to obtain a linear regression equation,tested the effect of serum miR-153 and miR-128b on non-motor symptoms in patients with Parkinson’s disease. Results　Theexpression profiles of serum miR-153 and miR-128b and NMSS score before treatment >at 4w >8w >12w of treatment, there wasa statistical significant difference (F=7.640, 134.902, 18.048, all P<0.05). The correlation analysis showed that the NMSS scorehad positive correlation with the expression profiles of serum miR-153 and miR-128b (r=0.246, 0.486, all P<0.001). The linearregression equation of serum miR-153 was obtained by linear regression analysis: Y=13.656+1.704X, serum miR-128b:Y=13.656+22.661X, and the level of serum miR-128b in patients with Parkinson’s disease might be the influencing factor of non-motor symptoms (P<0.05). Conclusion　The expression profiles of serum miR-153 and miR-128b in patients withParkinson’s disease were closely related to non-motor symptoms. Clinically, the expression profiles of serum miR-153 and miR-128b can be monitored and intervened to relieve non-motor symptoms and improve prognosis in patients with Parkinson’sdisease.

参考文献/References:

[1] MICHAL FREEDMAN D, WU Jincao, CHENHonglei, et al. Associations between cancer andParkinson’s disease in U.S. elderly adults[J].International Journal of Epidemiology, 2016, 45(3):741-751.
[2] GOEDERT M, COMPSTON A. Parkinson’s disease -the story of an eponym[J]. Nature Reviews Neurology,2018, 14(1): 57-62.
[3] ARMSTRONG R A. Visual dysfunction in Parkinson’sdisease[J]. International Review of Neurobiology, 2017,134(6): 921-946.
[4] 周梅，余丹．血清微小RNA-221, 微小RNA-214 在帕金森病中的表达及其与帕金森综合评分的相关性研究[J]. 中国医刊, 2020, 55 (2): 206-209．ZHOU Mei, YU Dan. Research on expression of serummicroRNA-221 and microRNA-214 in Parkinson’sdisease and their correlation with Parkinson’scomprehensive score [J]. Chinese Medical Journal,2020, 55 (2): 206-209.
[5] WANG Jin, CHEN Jinyun, SEN S. MicroRNA asbiomarkers and diagnostics[J]. Journal of CellularPhysiology, 2016, 231(1): 25-30.
[6] LIN Yihai, WU Zhangyi. MicroRNA-128 inhibitsproliferation and invasion of glioma cells by targetingCOX-2[J]. Gene, 2018, 658(6): 63-69.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南( 第三版)[J]. 中华神经科杂志,2014,43(6):428-433.Chinese Society of Parkinson’s Disease and MovementDisorders. Chinese guidelines for the treatment ofParkinson’s disease (3rd Edition) [J]. Chinese Journalof Neurology, 2014, 43 (6): 428-433
[8] STORCH A, SCHNEIDER C B, KLINGELH?FERL, et al. Quantitative assessment of non-motorfluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS)[J]. Journal of NeuralTransmission (Vienna, Austria : 1996), 2015, 122(12):1673-1684.
[9] 刘郁，张静静，吕荣祥，等．miR-143-3p 和BCL2在早发性帕金森病患者血清胞外囊泡中异常表达[J]. 中华神经医学杂志,2019,18(1):17-21.LIU Yu, ZHANG Jingjing, L? Rongxiang, et al.Abnormal expressions of micro RNA-143-3p and B-celllymphoma-2 in serum extracellular vesicles of patientswith early-onset Parkiuson’s disease [J]. ChineseJournal of Neuromedicine, 2019, 18 (1): 17-21
[10] 乔迪, 江沛, 伊新艳, 等. 微小RNA 在帕金森病中调节α- 突触核蛋白表达的研究进展[J]. 中南药学,2017,15(8):1085-1088.QIAO Di, JIANG Pei, YI Xinyan, et al. Role ofmicroRNAs in regulating α-synuclein expression inParkinson’s disease [J]. Central South Pharmacy, 2017,15 (8): 1085-1088.
[11] LEE H C, JUNG S H, HWANG H J, et al. WIG1is crucial for AGO2-mediated ACOT7 mRNAsilencing via miRNA-dependent and -independentmechanisms[J]. Nucleic Acids Research, 2017, 45(11):6894-6910.
[12] WANG C, GUPTA P, FRESSIGNE L, et al. TEG-1CD2BP2 controls miRNA levels by regulating miRISCstability in C. elegans and human cells[J]. NucleicAcids Research, 2017, 45(3): 1488-1500.
[13] ZANGARI J, ILIE M, ROUAUD F, et al. Rapid decayof engulfed extracellular miRNA by XRN1 exonucleasepromotes transient epithelial-mesenchymal transition[J].Nucleic Acids Research, 2017, 45(7): 4131-4141.
[14] 韩凯． 血清miR-103a,miR-30b,miR-29a 相对表达量对帕金森病的诊断效能[J]. 山东医药,2017,57(11):72-74.HAN Kai. Diagnostic efficacy of serum relativeexpression levels of miR-103a, miR-30b and miR-29afor Parkinson’s disease [J]. Shandong Medical, 2017,57 (11): 72-74.
[15] 许思, 王丽华, 王健健, 等. 神经系统疾病与循环microRNA 的研究进展[J]. 国际遗传学杂志, 2016,39(3):169-175.XU Si, WANG Lihua, WANG Jianjian, et al. Progressin studying on the relationship between nervous systemdiseases and circulating microRNA [J]. InternationalJournal of Genetics, 2016, 39 (3): 169-175.
[16] 张强, 王明洪, 甘敏, 等. 首发精神分裂症患者血清微小RNA-181c 水平与认知功能相关性分析[J]．临床军医杂志, 2019, 47(9):965-966, 969.ZHANG Qiang, WANG Minghong, GAN Min, et al.Analysis on correlation between serum microRNA-181c level and cognitive function in patients with firstepisodeschizophrenia [J]. Clinical Journal of MedicalOfficers, 2019, 47 (9): 965-966, 969.
[17] 李泓江，孙兆良，杨西涛．microRNA 在中枢神经系统神经再生中作用[J]. 中国临床神经外科杂志，2016,21(10):646-648.LI Hongjiang, SUN Zhaoliang, YANG Xitao.The role of microRNA in central nervous systemnerve regeneration [J]. Chinese Journal of ClinicalNeurosurgery, 2016, 21 (10): 646-648.
[18] 王敏，聂思佩，朱玲玲，等. miR-206 调节的血清IGF-1 水平与2 型糖尿病伴发帕金森病的相关性研究 [J]. 药物评价研究, 2017, 40 (12): 1735-1740.WANG Min, NIE Sipei, ZHU Lingling, et al.Correlation study between serum IGF-1 levels regulatedby miR-206 and diabetes mellitus accompanied withParkinson’s disease [J]. Drug Evaluation Research,2017, 40 (12): 1735-1740.
[19] 王征，李艳芳．microRNA-146a 在2 型糖尿病周围神经病变患者血清中的表达及其临床意义[J]. 中国慢性病预防与控制,2019,27(1):28-31.WANG Zheng, LI Yanfang. Expression levels andclinical significance of serum microRNA-146a inpatients with type 2 diabetes mellitus plus diabeticperipheral neumpathy [J]. Chinese Journal ofPrevention and Control of Chronic Diseases, 2019,27(1): 28-31.
[20] 徐瑞, 刘贤, 牛梦月, 等.MiR-133b 对MPP+ 诱导的帕金森病多巴胺能神经元模型中酪氨酸羟化酶表达的影响[J]. 中国临床神经科学,2016,24(2):133-138.XU Rui, LIU Xian, NIU Mengyue, et al. Effect ofmiR-133b on expression of tyrosine hydroxylase in ratdopaminergic neuron primary culture injured by MPP+[J]. Chinese Journal of Clinical Neurosciences, 2016,24 (2): 133-138.

相似文献/References:

[1]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(05):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(05):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(05):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[6]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(05):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[7]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(05):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[8]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(05):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[9]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(05):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
作者简介：李群英（1979-），女，硕士学历，主管技师，专业：临床检验技术，E-mail: oocp0236@163.com。
更新日期/Last Update: 1900-01-01